Irbesartan

證據等級: L5

預測適應症: 4 個

Irbesartan: From Hypertension to Malignant Renovascular Hypertension

One-Sentence Summary

Irbesartan is an angiotensin II receptor blocker (ARB), a class of drugs whose established use is treating hypertension. The TxGNN model predicts it may be effective for Malignant Renovascular Hypertension, but this direction is currently supported by 0 clinical trials and 0 publications — the signal rests on the model's mechanistic score alone.

Quick Overview

Item	Content
Original Indication	Hypertension (ARB class; the drug is not marketed in Finland, so no approved-label indication text is available)
Predicted New Indication	Malignant Renovascular Hypertension
TxGNN Prediction Score	99.31%
Evidence Level	L5
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this Evidence Pack (MOA field is a data gap). Based on known drug class information, irbesartan is an AT1 receptor antagonist (ARB) that inhibits the renin-angiotensin-aldosterone system (RAAS) to lower blood pressure — this is stated directly in the model's own repurposing rationale for this candidate.

The mechanistic logic connecting ARB pharmacology to malignant renovascular hypertension is genuinely double-edged, not a simple positive signal. On one hand, RAAS blockade is the standard pharmacological approach to severe hypertension. On the other, malignant renovascular hypertension frequently involves unilateral or bilateral renal artery stenosis, and ARBs dilate the efferent arteriole and reduce intraglomerular pressure — a well-known mechanism that can precipitate acute kidney injury specifically in bilateral renal artery stenosis. The same caveat applies to the closely related rank-2 candidate (malignant hypertensive renal disease), where renal function is often already compromised and ARB initiation requires close monitoring of creatinine and potassium.

The other two candidates in this pack (pulmonary hypertension due to lung disease/hypoxia, and pulmonary hypertension with unclear multifactorial mechanism — WHO Groups 3 and 5) are mechanistically weaker: these conditions are driven primarily by hypoxic pulmonary vasoconstriction and vascular remodeling rather than systemic RAAS activation, so ARB relevance is limited. Critically, the 20 literature records retrieved for the Group 3 candidate are all basic hypoxia biology, neurodegeneration, or oncology-hypoxia mechanism papers — none address irbesartan or ARBs in pulmonary hypertension, so they do not constitute supporting clinical evidence despite appearing in the search results.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Other TxGNN-Predicted Indications (Ranks 2–4)

Rank	Disease	Score	Evidence Level	Note
2	Malignant hypertensive renal disease	99.31%	L5	Same mechanistic caveat as Rank 1 (pre-existing renal impairment); no trials or literature
3	Pulmonary hypertension owing to lung disease and/or hypoxia	99.25%	L5	20 literature hits, all unrelated hypoxia-biology/oncology papers — no ARB-specific clinical evidence
4	Pulmonary hypertension with unclear multifactorial mechanism	99.25%	L5	No mechanistic pathway clearly linked to ARB activity; no trials or literature

All four candidates are scored L5 (model prediction only) with a Hold recommendation at decision stage S0.

Finland Market Information

Irbesartan currently has no marketing authorization in Finland (market status: Not marketed; 0 licenses on file). No approved indication text is available from this jurisdiction.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all unavailable in this Evidence Pack — the DDI query also returned no results.)

Conclusion and Next Steps

Decision: Hold

Rationale: No candidate indication in this pack has clinical trial or literature support, and the top-ranked candidate carries a known mechanistic risk (potential acute kidney injury in bilateral renal artery stenosis) rather than a clean positive signal. Compounding this, the missing TFDA/Fimea package-insert safety data (contraindications and warnings) is flagged as a Blocking gap that by itself prevents this candidate from entering S1 safety review.

To proceed, the following is needed:

Package insert warnings and contraindications (Blocking gap — required before any S1 safety evaluation)
Detailed mechanism-of-action data to properly assess mechanistic fit for renal-hypertension indications
Clinical or real-world evidence specifically evaluating ARB use in malignant renovascular hypertension / malignant hypertensive renal disease, including renal-artery-stenosis screening protocols
Route and dosage-form compatibility data, since Finland has no existing marketing authorization to reference
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.